Printer Friendly

Articles from M2 Pharma (August 4, 2017)

1-19 out of 19 article(s)
Title Author Type Words
AgeX Therapeutics Secures USD 10m Funding to Develop Age-Related Disease Treatments. 269
Celgene's Abraxane will be available through the Cancer Drugs Fund in England. 268
Chondrial awarded US FDA's orphan drug designation for CTI-1601 for Friedreich's Ataxia. 227
Citius expects gross proceeds of USD6.8m from public offering. 210
CTI BioPharma reports financial results for H1 2017. Financial report 104
FDA Advisory Committee Votes in Favour of Xeljanz (tofacitinib citrate) for the Treatment of Active Psoriatic Arthritis. 376
Foamix doses first patient with FMX101 under third Phase 3 acne study. 277
Jazz Pharmaceuticals wins US FDA approval for Vyxeos for acute myeloid leukemia. 253
Madison Vaccines Doses First Patient in Trial of MVI-816 Plus Keytruda for Metastatic, Treatment-Resistant Prostate Cancer. 308
NIAID Awards Integrated BioTherapeutics USD 6.6m Grant for Development of Pan-Ebolavirus Vaccine in Collaboration with The Scripps Research Institute. 406
NIH Awards BioAxone BioSciences USD 1.5m SBIR Grant. 248
Orbsen Therapeutics receives approval for OBRCEL-M in Europe. 128
Oriola reports on share repurchase. 101
Results of Kite Study of Refractory Aggressive Non-Hodgkin Lymphoma Published in Electronic Edition of BLOOD. 364
Swift Biosciences Launches New Indexed Adapters for Sequencing Larger Numbers of Samples. 371
Tonic Life Communications names new senior vice president. 122
US FDA Approves of AbbVie's Mavret for the Treatment of Chronic Hepatitis C in All Major Genotypes. 387
USFDA grants priority review to AstraZeneca's acalabrutinib. 163
Virta Health Names Former CMS Head Berwick Joins Board of Directors. 350

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters